Clinical trial · Observational
Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients
Investigate the Real-life Treatment Outcome of Regorafenib in Treating mCRC Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Regorafenib is currently the standard of care for refractory mCRC patients. Pivotal studies of regorafenib have proven the efficacy and safety, with a 28-day cycle (21 days on, 7 days off) and 160 mg dose given once daily. In the clinic, patients often have some complicated condition. This study aims to perform retrospective medical chart review of mCRC patients who received regorafenib treatment in two medical centers in Taiwan to examine treatment effectiveness in the routine clinical practice setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Regorafenib | Drug | Regorafenib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Effectiveness of regorafenib use in routine clinical practice setting, assessed by overall survival (OS)
- timeFrame
- through study completion, estimated 2 years
- description
- months
- measure
- Effectiveness of regorafenib use in routine clinical practice setting, assessed by progression free survival (PFS)
- timeFrame
- through study completion, estimated 2 years
- description
- months
- measure
- Effectiveness of regorafenib use in routine clinical practice setting, assessed by time to progression (TTP)
- timeFrame
- through study completion, estimated 2 years
- description
- months
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * mCRC patients who received at least one dose of regorafenib treatment Exclusion Criteria: * \<=20 y/o * Patients who did not receive regorafenib treatment will be excluded from the analysis * Patients with incomplete medical records that are deemed ineligible for analysis by investigator
References
Publications (1)
- DERIVEDHsu HC, Huang KC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang TS, Chen CC, Chao Y, Teng HW. Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread. Sci Rep. 2021 Jul 28;11(1):15370. doi: 10.1038/s41598-021-94968-x. PMID 34321583